[go: up one dir, main page]

JP2005336090A - Disintegrant for tablets - Google Patents

Disintegrant for tablets Download PDF

Info

Publication number
JP2005336090A
JP2005336090A JP2004156182A JP2004156182A JP2005336090A JP 2005336090 A JP2005336090 A JP 2005336090A JP 2004156182 A JP2004156182 A JP 2004156182A JP 2004156182 A JP2004156182 A JP 2004156182A JP 2005336090 A JP2005336090 A JP 2005336090A
Authority
JP
Japan
Prior art keywords
disintegrant
tablets
present
anion
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004156182A
Other languages
Japanese (ja)
Inventor
Shigeo Miyata
宮田茂男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sea Water Chemical Institute Inc
Original Assignee
Sea Water Chemical Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sea Water Chemical Institute Inc filed Critical Sea Water Chemical Institute Inc
Priority to JP2004156182A priority Critical patent/JP2005336090A/en
Publication of JP2005336090A publication Critical patent/JP2005336090A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

【課題】医薬品等の錠剤において、高レベルの成型物強度を発現すると共に、錠剤を服用した時は優れた崩壊性を示す、相矛盾した要求を同時に満足させることのできる崩壊剤を提供する。
【解決手段】下記式(1)
【化1】

Figure 2005336090

{式中、An−はCl,CO 2−等のSO 2−以外のn価(nは1以上の整数)のアニオンを示し、x,y,zおよびmはそれぞれ次の範囲を示す、2<x≦10,0.5<y<1.5,0≦z<0.5,0≦m<20}で表されるSO型ハイドロタルサイト類を使用する。
【選択図】なし
Disclosed is a disintegrant capable of satisfying contradictory demands at the same time, exhibiting a high level of molding strength in tablets such as pharmaceuticals, and exhibiting excellent disintegration properties when taking tablets.
The following formula (1)
[Chemical 1]
Figure 2005336090

{Wherein, A n-is Cl -, CO 3 SO 4 2- Other n-valent 2- like (n is an integer of 1 or more) denotes an anion of, x, y, z and m ranges follows respectively SO 4 type hydrotalcites represented by 2 <x ≦ 10, 0.5 <y <1.5, 0 ≦ z <0.5, 0 ≦ m <20} are used.
[Selection figure] None

Description

本発明は、錠剤、造粒物用崩壊剤に関する。   The present invention relates to a disintegrant for tablets and granules.

従来、錠剤とか造粒物(顆粒)に使用する崩壊剤としては、カルボキシメチルセルロースカルシウム、デンプン、グアーガム、CMC−Na、アラビアガム、PVA、マンニトール、ソルビトール、エリスリトールなどが使用されている。   Conventionally, carboxymethylcellulose calcium, starch, guar gum, CMC-Na, gum arabic, PVA, mannitol, sorbitol, erythritol and the like have been used as disintegrants used for tablets and granulated products (granules).

錠剤とか顆粒は経口摂取後、胃や腸の消化液中で崩壊し、薬効成分を放出し、胃や腸で吸収させるものであるが、取り扱い時は形状が安定して保持されながら(高い機械的強度)、消化液中での崩壊、できれば口内での崩壊を充分に行わせることが必要である。   Tablets and granules disintegrate in the digestive juices of the stomach and intestines after ingestion, release medicinal ingredients and absorb them in the stomach and intestines. Strength), disintegration in digestive juice, preferably disintegration in the mouth is necessary.

上記2つの要求特性はうらはらの関係にあり、錠剤の機械的強度が高くなるほど崩壊性が悪くなり、逆に崩壊性を良くするほど錠剤の機械的強度は悪くなる傾向にある。したがって、従来の崩壊剤は、崩壊性は良いが錠剤の機械的強度に難がある。   The above two required characteristics are in a back-to-back relationship, and the higher the mechanical strength of the tablet, the worse the disintegration property. Conversely, the better the disintegration property, the worse the mechanical strength of the tablet. Therefore, the conventional disintegrants have good disintegration properties but have difficulty in the mechanical strength of tablets.

本発明は、下記式(1)

Figure 2005336090
{式中、An−はCl,CO 2−等のSO以外のn価(nは1以上の整数)のアニオンを示し、x,y,zおよびmはそれぞれ次の範囲を示す。2<x≦10,0.5<y<1.5,0≦z<0.5,0≦m<20}で表されるSOを層間アニオンの主成分として含有するハイドロタルサイト類を有効成分とする錠剤用崩壊剤を提供する。 The present invention provides the following formula (1)
Figure 2005336090
{In the formula, A n- represents an anion of n valence (n is an integer of 1 or more) other than SO 4 such as Cl , CO 3 2− , and x, y, z, and m each represent the following ranges. . Hydrotalcites containing SO 4 represented by 2 <x ≦ 10, 0.5 <y <1.5, 0 ≦ z <0.5, 0 ≦ m <20} as a main component of an interlayer anion Disintegrating agents for tablets as active ingredients are provided.

本発明によれば、高い錠剤強度(形状安定性)を示しながら、水と接触すると、急速に層間に水が取り込まれて層間隔が拡大、膨張し、極めて短時間に崩壊に至らしめることができる。本発明の崩壊剤は、同時に優れた賦形剤として機能する。   According to the present invention, when it comes into contact with water while exhibiting high tablet strength (shape stability), water is rapidly taken in between the layers, the layer interval is expanded and expanded, and can be collapsed in a very short time. it can. The disintegrant of the present invention simultaneously functions as an excellent excipient.

本発明によれば、相矛盾する2つの要求である、優れた賦形剤の性能と優れた崩壊剤の性能を一つの物質で代替できる。極めて崩壊性に優れているため、水無しでも経口服用できる錠剤を提供できる。   According to the present invention, two contradictory requirements, which are excellent excipient performance and excellent disintegrant performance, can be replaced by one substance. Since it is extremely disintegrating, it can provide tablets that can be taken orally without water.

以下、本発明を詳細に説明する。本発明の崩壊剤はSOを層間アニオンの主成分とする[化1]で表されるハキイドロタルサイト類である。SOはSを4個の酸素が取り囲む四面体をしており、層間にあって、MgとAlの水酸化物が作る基本層の上または下の層のどちらかに強く結合しているが、片方の層とは結合が弱いため、そして、層間隔がCO型などに比べて大きいため、ハイドロタルサイト類の中にあって唯一と言っていい程、水が層間に可逆的に浸入、膨潤しやすいことを本発明者は発見した。約40〜50℃以上の乾燥でSOが占める層間に、層間水は一層存在するが、水に接触すると直ちに水を層間に取り込み、水の層が2層以上形成されるようになる。この層間水増大による層間隔の拡大(約2〜3オングストローム以上)が、従来の崩壊剤を凌ぐ、極めて短時間での崩壊の原因と考えられる。 Hereinafter, the present invention will be described in detail. The disintegrant of the present invention is a haloid rothalite represented by [Chemical Formula 1] containing SO 4 as a main component of an interlayer anion. SO 4 has a tetrahedron surrounded by four oxygen atoms in S 4, and is strongly bonded to either the upper layer or the lower layer formed by the hydroxide of Mg and Al in the interlayer. Since the bonding with one layer is weak and the inter-layer spacing is large compared to CO 3 type etc., water is reversibly infiltrated between layers as much as it is the only one among hydrotalcites, The present inventor has discovered that it is easy to swell. One layer of interlayer water is present between the layers occupied by SO 4 by drying at about 40 to 50 ° C. or higher. However, as soon as it comes into contact with water, water is taken in between the layers and two or more layers of water are formed. This increase in interlayer spacing (about 2 to 3 angstroms or more) due to the increase in interlayer water is considered to be a cause of disintegration in a very short time, exceeding that of conventional disintegrants.

本発明の崩壊剤であるSO型ハイドロタルサイト類は、1次粒子が小さく、2次粒子も小さいほど好ましく、そのような物がより優れた賦形性(打錠硬度)を示す。[化1]において、層間全アニオンに占めるSOイオンの割合は、前記説明で明らかなごとく、高いほど好ましい。換言すれば、SO以外のアニオンであるAn−の量が少ない物がより好ましい。 The SO 4 type hydrotalcites that are the disintegrants of the present invention are preferably such that the primary particles are small and the secondary particles are small, and such a product exhibits better formability (tablet hardness). In [Chemical Formula 1], the higher the proportion of SO 4 ions in the total interlayer anions, the more preferable as it is apparent from the above description. In other words, those amounts of A n- is an anion other than SO 4 is less is more preferable.

SO型ハイドロタルサイト類の製造は従来公知である。例えば、硫酸マグネシウムと硫酸アルミニウムの混合水溶液と水酸化ナトリウムの水溶液を、pHを約9以上に保って共沈させる方法で実施できる。また或いは、塩化マグネシウムと塩化アルミニウムの混合水溶液と水酸化ナトリウムの水溶液とを用い、pHを約9以上に保ってCl型ハイドロタルサイト類を共沈させた後、硫酸ナトリウムとか硫酸マグネシウムで洗浄して、ClをSO 2−でイオン交換する方法でも製造できる。以上のごとき方法で製造される本発明の崩壊剤として好適なSO型ハイドロタルサイト類としては、例えば下記式(2)および(3)を挙げることができる。

Figure 2005336090
Figure 2005336090
The production of SO 4 type hydrotalcites is conventionally known. For example, a mixed aqueous solution of magnesium sulfate and aluminum sulfate and an aqueous solution of sodium hydroxide can be co-precipitated while maintaining the pH at about 9 or higher. Alternatively, a mixed aqueous solution of magnesium chloride and aluminum chloride and an aqueous solution of sodium hydroxide are used to coprecipitate Cl-type hydrotalcites while maintaining the pH at about 9 or higher, and then washed with sodium sulfate or magnesium sulfate. Thus, it can also be produced by a method in which Cl is ion exchanged with SO 4 2− . Examples of the SO 4 -type hydrotalcites suitable as the disintegrant of the present invention produced by the above method include the following formulas (2) and (3).
Figure 2005336090
Figure 2005336090

本発明の崩壊剤の形態は、粉末またはスプレードライ(噴霧乾燥)造粒物であり、流動性に優れた後者がより好ましい。本発明の崩壊剤を用いる錠剤の成型には、次に示す既知の崩壊剤、賦形剤、滑剤等を併用して用いることができる。崩壊剤には、デンプン系、セルロース系、ビニール系、糖アルコール系等の崩壊剤、例えばトウモロコシデンプン、ばれいしょデンプン、デキストリン、ヒドロキシプロピルスターチ、部分アルファ化デンプン、カルボキシメチルスターチナトリウム等のデンプン系;カルメロースカルシウム、カルメロース、カルボキシメチルセルロースナトリウム、カルボキシメチルセルロースカルシウム等のセルロース系;ポリビニルアルコール(PVA)、架橋ポリビニルピロリデン等のビニル系;マンニトール、ソルビトール、エリスリトール、キシリトール、マルチトール、ラクチトール等の糖アルコール類を用いることができる。賦形剤としては、例えば乳糖、微結晶セルロース、リン酸水素カルシウム、マンニトール、ヒドロキシプロピルメチルセルロース、カルボキシメチルセルロースカルシウム等を用いることができる。滑剤としては、例えばステアリン酸マグネシウム、ステアリン酸カルシウム、タルク等を用いることができる。崩壊剤、賦形剤、滑剤の本発明崩壊剤に対する配合量は、それぞれ1〜20重量%、1〜50重量%、1〜10重量%である。以下、実施例により本発明をより詳細に説明するが、本発明はこれらのみに限定されるものではない。   The form of the disintegrant of the present invention is a powder or a spray-dried (spray-dried) granulated product, and the latter having excellent fluidity is more preferable. For molding tablets using the disintegrant of the present invention, the following known disintegrants, excipients, lubricants and the like can be used in combination. Disintegrants include starch-based, cellulose-based, vinyl-based, sugar-alcohol-based disintegrants such as corn starch, potato starch, dextrin, hydroxypropyl starch, partially pregelatinized starch, and carboxymethyl starch sodium; Cellulose type such as roast calcium, carmellose, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium; vinyl type such as polyvinyl alcohol (PVA), cross-linked polyvinyl pyrrolidene; sugar alcohols such as mannitol, sorbitol, erythritol, xylitol, maltitol, lactitol Can be used. As the excipient, for example, lactose, microcrystalline cellulose, calcium hydrogen phosphate, mannitol, hydroxypropylmethylcellulose, carboxymethylcellulose calcium and the like can be used. As the lubricant, for example, magnesium stearate, calcium stearate, talc and the like can be used. The blending amounts of the disintegrant, excipient, and lubricant with respect to the disintegrant of the present invention are 1 to 20% by weight, 1 to 50% by weight, and 1 to 10% by weight, respectively. EXAMPLES Hereinafter, although an Example demonstrates this invention in detail, this invention is not limited only to these.

硫酸マグネシウムと硫酸アルミニウムの混合水溶液(Mg=2モル/リットル,Al=1モル/リットル)と4モル/リットルの水酸化ナトリウムの水溶液を、容量2リットルのオーバーフロー付き反応槽に、MgとAlの混合液を100ml/分、アルカリを約150mlとし、反応槽でpHが約9.6〜9.8になるように、アルカリの供給量を調整して供給し、約40℃で共沈反応させた。この後、ろ過、水洗し、約120℃で乾燥、粉砕した。得られた粉末のX線回析を測定した結果、単位層厚に相当する(003)面の面間隔は、8.3Åのハイドロタルサイト類のみの回析パターンを示した。この粉末を塩酸に溶解して化学分析を行うとともに熱分析を行って結晶水量を測定して求めた化学組成は次の通りであった。
Mg4.1Al(OH)12(SO1.1・2H
A mixed aqueous solution of magnesium sulfate and aluminum sulfate (Mg = 2 mol / liter, Al = 1 mol / liter) and an aqueous solution of 4 mol / liter sodium hydroxide were placed in a reaction tank with an overflow of 2 liters and a Mg / Al solution. The mixed solution is 100 ml / min, the alkali is about 150 ml, the alkali is supplied in an amount of about 9.6 to 9.8 in the reaction tank, and the coprecipitation reaction is carried out at about 40 ° C. It was. Then, it filtered, washed with water, dried at about 120 ° C. and pulverized. As a result of measuring the X-ray diffraction of the obtained powder, the (003) plane spacing corresponding to the unit layer thickness showed a diffraction pattern of only 8.3 mm hydrotalcites. The chemical composition obtained by dissolving this powder in hydrochloric acid and conducting chemical analysis and thermal analysis to measure the amount of water of crystallization was as follows.
Mg 4.1 Al 2 (OH) 12 (SO 4 ) 1.1 · 2H 2 O

[錠剤の作成]
この粉末、SO型ハイドロタルサイト類54重量%、アスコルビン酸(試薬1級)40重量%、PVA(試薬)5重量%、ステアリン酸マグネシウム(試薬)1重量%を均一に混合後、打錠機を用い、厚さ4mm、直径12mm、重量約800mgの錠剤を成型圧600kgで作成した。得られた錠剤について、キヤ式硬度計で5個測定し、その平均値から硬度(kg)を、日本薬局法に準拠し、各3錠にて水中で完全に分散するのに要する時間(秒)から崩壊性を測定した。その結果を表1に示す。
[Making tablets]
This powder, 54% by weight of SO 4 type hydrotalcite, 40% by weight of ascorbic acid (reagent grade 1), 5% by weight of PVA (reagent), and 1% by weight of magnesium stearate (reagent) are mixed uniformly, and then tableted. Using a machine, a tablet having a thickness of 4 mm, a diameter of 12 mm, and a weight of about 800 mg was prepared at a molding pressure of 600 kg. About the obtained tablets, 5 pieces were measured with a carrier type hardness tester, and the time (seconds) required to completely disperse the hardness (kg) from the average value in water in 3 tablets each according to the Japanese Pharmacy Law. ) To measure disintegration. The results are shown in Table 1.

実施例1において、硫酸マグネシウムと硫酸アルミニウムの混合水溶液として、Mg=3モル/リットル,Al=1モル/リットルの濃度の溶液を用いる以外は、実施例1と同様に行った。得られた粉末のX線回析は、(003)面の面間隔が8.6Åのハイドロタルサイト類のみの回析パターンを示した。この物の化学分析と熱分析を行って求めた化学組成は次の通りであった。
MgAl(OH)15.8(SO0.9(CO0.2・4H
このSO型ハイドロタルサイト粉末を用い、実施例1と同様にして錠剤を作製し、硬度と崩壊性を測定した。その結果を表1に示す。
In Example 1, it carried out like Example 1 except using the solution of the density | concentration of Mg = 3 mol / liter and Al = 1 mol / liter as mixed aqueous solution of magnesium sulfate and aluminum sulfate. X-ray diffraction of the obtained powder showed a diffraction pattern of only hydrotalcites having a (003) plane spacing of 8.6 mm. The chemical composition obtained by conducting chemical analysis and thermal analysis of this product was as follows.
Mg 6 Al 2 (OH) 15.8 (SO 4 ) 0.9 (CO 3 ) 0.2 · 4H 2 O
Using this SO 4 type hydrotalcite powder, tablets were prepared in the same manner as in Example 1, and the hardness and disintegration were measured. The results are shown in Table 1.

[比較例1]
実施例1の錠剤作製において、本発明のSO型ハイドロタルサイト類の代わりに、代表的な賦形剤である微結晶セルロース(アビセルPH101,旭化成工業製)を用いる以外は、実施例1と同様に行って、錠剤の硬度と崩壊性を測定した。その結果を表1に示す。
[Comparative Example 1]
Example 1 is the same as Example 1 except that microcrystalline cellulose (Avicel PH101, manufactured by Asahi Kasei Kogyo Co., Ltd.), which is a representative excipient, is used instead of the SO 4 type hydrotalcites of the present invention. In the same manner, the hardness and disintegration of the tablets were measured. The results are shown in Table 1.

[比較例2]
実施例1の錠剤作製において、SO型ハイドロタルサイト類の代わりに、微結晶セルロースを51重量%と、崩壊剤であるカルボキシメチルセルロースナトリウム(商品名 DST−SF)を3重量%加えた組成で、実施例1と同様にして錠剤を作製し、硬度と崩壊時間を測定した。その結果を表1に示す。
[Comparative Example 2]
In the preparation of the tablet of Example 1, in place of SO 4 type hydrotalcite, 51% by weight of microcrystalline cellulose and 3% by weight of disintegrant sodium carboxymethyl cellulose (trade name DST-SF) were added. A tablet was prepared in the same manner as in Example 1, and the hardness and disintegration time were measured. The results are shown in Table 1.

Figure 2005336090
Figure 2005336090

表1の結果から、本発明の崩壊剤は優れた成型強度を示すと共に、極めて優れた崩壊性を示すことが判る。
From the results of Table 1, it can be seen that the disintegrant of the present invention exhibits excellent molding strength and extremely excellent disintegration properties.

Claims (3)

下記式(1)
Figure 2005336090
{式中、An−はCl,CO 2−等のSO 2−以外のn価(nは1以上の整数)のアニオンを示し、x,y,zおよびmはそれぞれ次の範囲を示す。2<x≦10,0.5<y<1.5,0≦z<0.5,0≦m<20}で表されるSOを層間アニオンの主成分として含有するハイドロタルサイト類を有効成分とする錠剤用崩壊剤。
Following formula (1)
Figure 2005336090
{Wherein, A n-is Cl -, CO 3 SO 4 2- Other n-valent 2- like (n is an integer of 1 or more) denotes an anion of, x, y, z and m ranges follows respectively Indicates. Hydrotalcites containing SO 4 represented by 2 <x ≦ 10, 0.5 <y <1.5, 0 ≦ z <0.5, 0 ≦ m <20} as a main component of an interlayer anion Disintegrant for tablets as an active ingredient.
[化1]において、xおよびyが次の範囲、x=3〜7,0.8<y<1.5であることを特徴とする請求項1記載の錠剤用崩壊剤。 The disintegrant for tablets according to claim 1, wherein x and y are in the following ranges, wherein x = 3 to 7, 0.8 <y <1.5. [化1]で表される崩壊剤の重量に基づいて、1〜50重量%のデンプン系、セルロース系、ビニール系、糖アルコール系等の崩壊剤を併用することを特徴とする請求項1記載の崩壊剤。 The starch-based, cellulose-based, vinyl-based, sugar alcohol-based, etc. disintegrant based on the weight of the disintegrant represented by [Chemical Formula 1] is used in combination. Disintegrant.
JP2004156182A 2004-05-26 2004-05-26 Disintegrant for tablets Pending JP2005336090A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004156182A JP2005336090A (en) 2004-05-26 2004-05-26 Disintegrant for tablets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004156182A JP2005336090A (en) 2004-05-26 2004-05-26 Disintegrant for tablets

Publications (1)

Publication Number Publication Date
JP2005336090A true JP2005336090A (en) 2005-12-08

Family

ID=35490049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004156182A Pending JP2005336090A (en) 2004-05-26 2004-05-26 Disintegrant for tablets

Country Status (1)

Country Link
JP (1) JP2005336090A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006131581A (en) * 2004-11-09 2006-05-25 Kyowa Chem Ind Co Ltd Disintegrator and disintegrable molded product containing the same
JP2011524461A (en) * 2008-06-20 2011-09-01 エクソンモービル・ケミカル・パテンツ・インク Functionalized, propylene-based oligomers with a high proportion of vinyl end groups

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006131581A (en) * 2004-11-09 2006-05-25 Kyowa Chem Ind Co Ltd Disintegrator and disintegrable molded product containing the same
JP2011524461A (en) * 2008-06-20 2011-09-01 エクソンモービル・ケミカル・パテンツ・インク Functionalized, propylene-based oligomers with a high proportion of vinyl end groups

Similar Documents

Publication Publication Date Title
JP5274261B2 (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
JP5798642B2 (en) Oral pharmaceutical composition
JP5342028B2 (en) Orally disintegrating tablets
EP2167046A2 (en) Pharmaceutical solid preparation comprising benzazepines and production method thereof
WO2013026553A1 (en) Composition comprising edoxaban
JP2008127349A (en) Solid composition
JP5433235B2 (en) Method for producing solid preparation
JP2018177657A (en) Levetiracetam-containing pharmaceutical composition and method for producing the same
JP6623753B2 (en) Orally disintegrating tablets containing lanthanum carbonate
JP2005336090A (en) Disintegrant for tablets
WO2013115746A1 (en) A production method for (effervescent) pharmaceutical compositions comprising an alpha - glucosidase inhibitor (miglitol) and metformin
JP4329947B1 (en) Tablets for internal use
CN112675192A (en) Hydrotalcite chewable tablet and preparation method thereof
JP2020158435A (en) Linagliptin-containing pharmaceutical composition and method for producing the same, and method for improving the quality of linagliptin-containing pharmaceutical composition
KR20160145904A (en) Preparation method for rapidly dissolving tablet containing phloroglucinol anhydrous with improved stability
JP7486258B2 (en) Granules for orally disintegrating tablets, their manufacturing method and orally disintegrating tablets
TW201249461A (en) A binder for forming a tablet
JP4174300B2 (en) Rapidly disintegrating tablet or orally disintegrating tablet containing L-glutamine and sodium azulenesulfonate and method for producing the same
CN103893192A (en) Cardiovascular disease treatment sustained-release tablets and preparation method thereof
CN101204395A (en) Orally disintegrating entecavir tablets
JP7012492B2 (en) Tablets and their manufacturing methods
JPWO2009151090A1 (en) Fast disintegrating preparation containing calcium carbonate
JP2006070022A (en) Cyclodextrin-containing drug or food additive
JP6198329B2 (en) Laminated tablet and method for producing the same
JP5282644B2 (en) Tablets for internal use